Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, today announced that Senthil Sundaram, the Company's recently retired Chief Executive Officer, passed away on November 22, 2023, following his battle with cancer.

Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

Announced global Phase 1 clinical trial design of TERN-701 (allosteric BCR-ABL) for CML with patient screening anticipated in December 2023 and interim top-line data expected in the second half of 2024

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

TERN-501 treatment over 12 weeks significantly improved liver fat content and fibro-inflammation in NASH patients, with low rates of gastrointestinal and no cardiovascular adverse events

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in the following upcoming investor conferences in November.

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

FOSTER CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of management will be participating in the following upcoming investor conferences:

Terns Pharmaceuticals to Participate in Upcoming Investor Conferences

Investigational New Drug application cleared by U.S. Food and Drug Administration Design leverages insights from partner's ongoing Phase 1 trial in China that support starting dose that appears safe and clinically active based on emerging early clinical data Patient screening anticipated in December 2023, with initial data expected in second half of 2024 FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced the U.S. Food and Drug Administration's (FDA's) clearance of the Company's Investigational New Drug application and the design of the CARDINAL Trial, Terns' global Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of TERN-701 in participants with chronic myeloid leukemia (CML).

Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

Terns Pharmaceuticals stock is down 15% in the past 10 months, despite bullish articles following a bearish prediction. The company initially planned to develop drugs for the Chinese market but switched to developing US drugs for US consumers. Terns' lead candidate TERN-501, a THR-β agonist, lacks convincing data and faces competition in the NASH market.

Terns Pharmaceuticals: Business Model Does Not Impress

Madrigal Pharmaceuticals

Viking Therapeutics

Many drug developers are pursuing therapies for those who supper from NASH. Madrigal Pharmaceuticals is waiting on the FDA's decision for its drug right now.

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

- Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 (THR-β) in NASH, with TERN-501 meeting all primary and secondary endpoints

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

Senthil Sundaram Stepping Down as Chief Executive Officer for Health Reasons Senthil Sundaram Stepping Down as Chief Executive Officer for Health Reasons

Terns Pharmaceuticals Announces Leadership Transition

TERN's TERN-701 is being developed for Chronic Myeloid Leukemia (CML), but NVS' Scemblix is similar and already approved. TERN-701 may offer benefits to Scemblix, some of which could become apparent as early as this year with some data from a partner's phase 1 trial. TERN's TERN-501 is set to produce data in Q3'23 from a phase 2a trial  in nonalcoholic steatohepatitis (NASH).

Terns Pharmaceuticals: Facing Impressive Competition, But Not Completely Out Of Its Depth

FOSTER CITY, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced it will host a virtual key opinion leader event to highlight the TERN-701 program and discuss advances in the treatment landscape for chronic myeloid leukemia (CML).

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA's 83rd Annual Scientific Session and Upcoming Events

FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that management will be participating in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT.

Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Terns Pharmaceuticals has a promising pipeline with potential best-in-class therapies for obesity and NASH. Upcoming data readouts for TERN-601 and TERN-501 could unlock value, with positive outcomes expected for both binary events. Terns is well-financed with cash runway into 2026, and I believe now is the ideal time to build a position.

Terns Pharmaceuticals: Upcoming Obesity Data Is One Of Many Catalysts Coming Up

- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

FOSTER CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that management will be participating in a fireside chat at the TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, May 31, 2023 at 3:00 p.m. ET. Terns management will also present at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023 at 12:30 p.m. ET.

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024 TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024

Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association's 83rd Annual Scientific Sessions

- Top-line data from Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) in NASH expected in third quarter of 2023

Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates

Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Terns Pharmaceuticals, Inc. (TERN) Is Up 15.12% in One Week: What You Should Know

Terns Pharmaceuticals released fourth-quarter and full-year earnings on Monday. The company is looking at therapies to treat various oncology targets, obesity, and non-alcoholic steatohepatitis (NASH).

Why Shares of Terns Pharmaceuticals Soared This Week

Akero Therapeutics Inc

89bio Inc

Intercept Pharma

Eli Lilly

Novo Nordisk

Pfizer

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

- Announces key appointments in oncology R&D and business development functions

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

TERN has a growing pipeline of early-stage assets against validated targets. TERN's internal discovery team has been productive at developing small molecules against key targets in big markets.

News for Terns Pharmaceuticals Stock (TERN)